3Chopt Investment Partners LLC Acquires 3,318 Shares of Gilead Sciences, Inc. $GILD

3Chopt Investment Partners LLC increased its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 17.6% in the 2nd quarter, according to its most recent filing with the SEC. The institutional investor owned 22,162 shares of the biopharmaceutical company’s stock after buying an additional 3,318 shares during the quarter. 3Chopt Investment Partners LLC’s holdings in Gilead Sciences were worth $2,457,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Southland Equity Partners LLC increased its holdings in shares of Gilead Sciences by 2.9% in the 2nd quarter. Southland Equity Partners LLC now owns 3,285 shares of the biopharmaceutical company’s stock valued at $364,000 after acquiring an additional 92 shares during the period. Twelve Points Wealth Management LLC boosted its position in Gilead Sciences by 1.5% during the second quarter. Twelve Points Wealth Management LLC now owns 6,499 shares of the biopharmaceutical company’s stock valued at $721,000 after purchasing an additional 98 shares in the last quarter. Argentarii LLC lifted its position in shares of Gilead Sciences by 3.0% during the first quarter. Argentarii LLC now owns 3,392 shares of the biopharmaceutical company’s stock valued at $380,000 after buying an additional 99 shares during the last quarter. Investment Research & Advisory Group Inc. lifted its position in shares of Gilead Sciences by 33.3% during the first quarter. Investment Research & Advisory Group Inc. now owns 400 shares of the biopharmaceutical company’s stock valued at $45,000 after buying an additional 100 shares during the last quarter. Finally, Lodestar Private Asset Management LLC lifted its position in shares of Gilead Sciences by 3.6% during the first quarter. Lodestar Private Asset Management LLC now owns 2,840 shares of the biopharmaceutical company’s stock valued at $318,000 after buying an additional 100 shares during the last quarter. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on the stock. UBS Group boosted their price objective on shares of Gilead Sciences from $108.00 to $112.00 and gave the stock a “neutral” rating in a research note on Friday, August 8th. Weiss Ratings reissued a “buy (b)” rating on shares of Gilead Sciences in a research report on Wednesday. Dbs Bank upgraded Gilead Sciences to a “moderate buy” rating in a research note on Friday, September 5th. Citigroup increased their price target on Gilead Sciences from $125.00 to $135.00 and gave the company a “buy” rating in a research note on Wednesday. Finally, Daiwa Capital Markets upgraded shares of Gilead Sciences from a “neutral” rating to an “outperform” rating and set a $128.00 price objective on the stock in a report on Tuesday, August 19th. Two research analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $118.08.

Insider Activity

In other news, CFO Andrew D. Dickinson sold 2,500 shares of the stock in a transaction dated Monday, September 15th. The shares were sold at an average price of $113.57, for a total transaction of $283,925.00. Following the sale, the chief financial officer directly owned 159,555 shares of the company’s stock, valued at $18,120,661.35. This represents a 1.54% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Daniel Patrick O’day sold 10,000 shares of the stock in a transaction dated Monday, July 28th. The stock was sold at an average price of $113.94, for a total transaction of $1,139,400.00. Following the sale, the chief executive officer directly owned 605,725 shares in the company, valued at approximately $69,016,306.50. The trade was a 1.62% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 82,000 shares of company stock valued at $9,402,130 in the last quarter. Company insiders own 0.27% of the company’s stock.

Gilead Sciences Trading Down 1.3%

Shares of Gilead Sciences stock opened at $116.74 on Friday. The firm has a fifty day moving average price of $114.57 and a 200 day moving average price of $110.19. The stock has a market cap of $144.85 billion, a PE ratio of 23.26, a price-to-earnings-growth ratio of 0.80 and a beta of 0.34. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.32 and a quick ratio of 1.15. Gilead Sciences, Inc. has a 1 year low of $84.17 and a 1 year high of $121.83.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share for the quarter, topping the consensus estimate of $1.96 by $0.05. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The company had revenue of $7.08 billion for the quarter, compared to the consensus estimate of $6.95 billion. During the same period last year, the firm earned $2.01 EPS. The firm’s revenue for the quarter was up 1.4% compared to the same quarter last year. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. Equities research analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, September 29th. Shareholders of record on Monday, September 15th were issued a $0.79 dividend. The ex-dividend date of this dividend was Monday, September 15th. This represents a $3.16 dividend on an annualized basis and a yield of 2.7%. Gilead Sciences’s payout ratio is presently 62.95%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.